Curated News
By: NewsRamp Editorial Staff
July 06, 2026

VERAXA Biotech Advances BiTAC Platform, Eyes Partnering Deals

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech's BiTAC platform and four solid tumor programs position it for lucrative pharma partnerships.
  • VERAXA advances four BiTAC T-cell engagers, two bispecific ADCs, and aims for IND/CTA readiness by early 2028.
  • VERAXA develops next-generation cancer therapies to improve outcomes for patients with solid tumors.
  • VERAXA's BiTAC platform originated from scientific breakthroughs at the European Molecular Biology Laboratory.

Impact - Why it Matters

This update matters because VERAXA’s progress with its BiTAC platform and growing pharma interest signals potential breakthroughs in solid tumor treatments. For investors, the company’s strategy to monetize non-BiTAC programs while prioritizing BiTAC could create value and reduce dilution risk. For patients, advancing VXA-102 toward IND/CTA readiness by 2028 brings hope for novel T-cell engager therapies. The broader oncology field benefits from VERAXA’s differentiated approach, which may lead to more effective and safer cancer immunotherapies.

Summary

VERAXA Biotech (NASDAQ: VRXA) has released a corporate and pipeline update highlighting its progress during the first half of 2026, with a strong focus on advancing its proprietary BiTAC(R) platform. The company reports growing interest from potential pharmaceutical partners, particularly in the T-cell engager and ADC technology spaces. VERAXA's pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs, and two non-BiTAC assets available for partnering. The company plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives highlighted strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The full press release can be viewed at https://ibn.fm/xTF5q.

VERAXA Biotech AG (NASDAQ: VRXA) is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s newsroom is available at http://ibn.fm/VRXA.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Advances BiTAC Platform, Eyes Partnering Deals

blockchain registration record for this content.